Table 1 Association of RAD51-AS1 expression with clinicopathological features of EOC patients.

From: E2F1-regulated long non-coding RNA RAD51-AS1 promotes cell cycle progression, inhibits apoptosis and predicts poor prognosis in epithelial ovarian cancer

Variable Low RAD51-AS1 expression (n = 65) High RAD51-AS1 expression (n = 64) P
  n (%) n (%)  
Age (years)
 <50 25 (38.5) 17 (26.6) 0.149
 ≥50 40 (61.5) 47 (73.4)  
Histological subtype
 Other 40 (61.5) 21 (32.8) 0.001
 Serous 25 (38.5) 43 (67.2)  
FIGO Stage
 I–II 46 (70.8) 21 (32.8) 0.000
 III–IV 19 (29.2) 43 (67.2)  
Histological grade
 Low 46 (70.8) 19 (29.7) 0.000
 High 19 (29.2) 45 (70.3)  
Tumor size (cm 3 )
 <1000 44 (67.7) 45 (70.3) 0.748
 ≥1000 21 (32.3) 19 (29.7)  
Number of tumors
 <2 39 (60.0) 21 (32.8) 0.002
 ≥2 26 (40.0) 43 (67.2)  
Residual tumor diameter (cm)
 <1 55 (84.6) 45 (70.3) 0.052
 ≥1 10 (15.4) 19 (29.7)  
Lymph node metastasis
 Absent 51 (78.5) 47 (73.4) 0.504
 Present 14 (21.5) 17 (26.6)  
Distant Metastasis
 Absent 48 (73.8) 27 (42.2) 0.000
 Present 17 (26.2) 37 (57.8)  
CA125 level (U/ml)
 <600 58 (89.2) 52 (81.3) 0.201
 ≥600 7 (10.8) 12 (18.8)  
Ascites
 Absent 53 (81.5) 43 (67.2) 0.062
 Present 12 (18.5) 21 (32.8)